Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-983-0 | CAS number: 90-30-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Objective of study:
- distribution
- excretion
- metabolism
- toxicokinetics
- Principles of method if other than guideline:
- - Kinetic determination of plasma and tissue radioactivity of rats following an oral dose of 14C-PNA.
- Determination of radioactivity in rat tissues 24 hours after administration of an oral dose of 14C-PNA.
- Radiolabeled PNA and metabolites were determined in urine samples pooled over 48 hours.
- Excretion was determined by investigation of total radioactivity in urine and feces of rats after various intervals of time following application of 14C-PNA. - GLP compliance:
- not specified
- Radiolabelling:
- yes
- Remarks:
- 14C
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Taconic Farms, Germantown, New York
- Weight at study initiation: 225 - 250 g
- Acclimation period: at least 1 week
ENVIRONMENTAL CONDITIONS
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- DMSO
- Duration and frequency of treatment / exposure:
- single exposure
- Dose / conc.:
- 160 mg/kg bw/day
- No. of animals per sex per dose / concentration:
- - Kinetics and Tissue distribution: 3 males per observation interval
- Metabolism and excretion: not specified - Control animals:
- not specified
- Details on study design:
- no information given
- Details on dosing and sampling:
- PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled (Plasma kinetics): blood, plasma
- Tissues and body fluids sampled (Tissue distribution): heart, lung, pancreas, spleen, kidney, testes, liver, fat, stomach, small intestine and contents, caeca, large intestine and contents
- Tissues and body fluids sampled (Excretion): urine, feces
- Time and frequency of sampling (Plasma kinetics): 0.5, 1, 2, 4, 8, 12, 16, 24, 48 and 72 hours
- Time and frequency of sampling (Tissue distribution): 24 hours; for tissue kinetics: 0.5, 1, 2, 4, 8, 12, 16, 24 and 48 hours
- Time and frequency of sampling (Excretion): 2, 4, 8, 12, 24, 32, 48, 72 and 120 hours
METABOLITE CHARACTERISATION STUDIES
- Tissues and body fluids sampled: urine
- Time and frequency of sampling: pooled over 48 hours
- From how many animals: no data on animal numbers, no data if individual samples were pooled, individual samples were pooled over sampling period
- Method type(s) for identification: HPLC-UV, Liquid scintillation counting
- Limits of detection and quantification: no data - Statistics:
- Percentage of radioactivity in urine extracts.
- Details on distribution in tissues:
- Kinetics: the concentration of total radioactivity in the plasma reached a peak of 116 µg PNA equivalents/ml four hours after dosing, thereafter it declined in a biphasic manner. About 3 % of the radioactivity in the plasma could be attributed to the parent compound 4 hours after dosing. The appearance and disappearance of plasma radioactivity shown was fitted to a pharmacokinetic two-compartment open-system model, in which a central blood compartment is in reversible equilibrium with a peripheral tissue compartment, with first-order-absorption. Analysis of the plasma radioactivity according to this relationship gave half-life values of 1.59 hr for the appearance process and 1.68 and 33 hr, respectively, for the two elimination processes. The level of unchanged PNA in the plasma followed a kinetic pattern similar to that of the total 14C but reached its peak level off 1.25 µg PNA/ml plasma at 2 hr after dosing, after which it declined in a biphasic manner. Analysis of the plasma levels of PNA gave half-life values of 0.66 hr for the appearance process and 1.24 and 11.1 hr, respectively, for the two disappearance processes.
Tissue distribution: Appreciable radioactivity was detected in all tissues at 24 hours indicating a rapid absorption and distribution of 14C-PNA and its metabolites. The major sites of distribution of 14C were fat, liver, kidney and lungs with large amounts in the gastro-intestinal tract plus contents. In all four major tissues (liver, fat, kidney, lung), radioactivity reached a maximum about 4 hours after dosing, reflecting a rapid uptake and distribution of the chemical. The levels of radioactivity then appeared to decrease in a biphasic manner. At all times, the highest concentration of 14C was found in the liver followed by fat, kidney, and lung. When radioactivity is expressed in terms of percent of the total dose received, only liver and fat are important tissues which retained most of the unexcreted radioactivity. - Details on excretion:
- More than 90 % of the administered dose had been excreted into the urine and feces within 48 hours of administration. The primary route of excretion of radioactivity was via the feces, although appreciable amounts of 14C were excreted via the urine. After 72 hours, 60 % of the total dose had been excreted in the feces and about 35 % in the urine. The bulk of the excretion in urine and feces occurred during the first 24 hours after administering the chemical.
- Metabolites identified:
- yes
- Details on metabolites:
- Urine contained a high percentage of 14C as materials which remained in the aqueous phase following extraction at pH 12 and 2, suggesting that PNA was extensively metabolized by the rat. HPLC analysis of the ether extract of the urine showed at least five 14C-metabolites (see table), no PNA could be detected in the ether extracts.
- Endpoint:
- basic toxicokinetics in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Objective of study:
- metabolism
- Principles of method if other than guideline:
- Identification of PNA-metabolites using rat liver microsomes from Aroclor 1254-induced rats.
- GLP compliance:
- not specified
- Radiolabelling:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Taconic Farms, Germantown, New York
- Weight at study initiation: 225 - 250 g
- Acclimation period: at least 1 week
ENVIRONMENTAL CONDITIONS
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- other: not applicable, in vitro
- Vehicle:
- DMSO
- Duration and frequency of treatment / exposure:
- 3 hours at 37°C
- Dose / conc.:
- 3.8 other: mg PNA/100mL
- No. of animals per sex per dose / concentration:
- not applicable, in vitro
- Control animals:
- other: not applicable
- Metabolites identified:
- yes
- Details on metabolites:
- Several metabolites were identfied: mono- and di-hydroxylated derivatives of PNA and the corresponding quinone derivatives, indicating further facile air oxidation of the metabolites during handling. In the Mono-hydroxy derivative, the hydroxy group is in the naphtalene moiety at the position para to the amino group. In the dihydroxy derivative, at least one hydroxy group is at the available para position in the naphtyl ring. Concerning the other hydroxy group the authors favour the idea of a localisation at the para position in the phenyl ring, although the existence of a hydroxy group in each ring of the naphtalene moiety cannot be excluded.
- Endpoint:
- basic toxicokinetics in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Objective of study:
- metabolism
- Principles of method if other than guideline:
- The induction of metabolism was investigated in liver microsomes from rats either with or without pre-treatment with metabolic inducers or the test substance itself. The metabolites formed out of the test substance were identified in experiments with freshly isolated rat hepatocytes.
- GLP compliance:
- not specified
- Radiolabelling:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Neuherberg, GSF Research Center Ger., inbred strain) - Route of administration:
- other: pre-treatment by intraperitoneal injection or oral gavage
- Vehicle:
- olive oil
- Duration and frequency of treatment / exposure:
- Pre-treatment: single i.p. injection, or repeatedly for 4 days or 8 days/3 weeks by oral gavage
- Dose / conc.:
- 200 other: mg/kg bw
- Remarks:
- i.p.
- Dose / conc.:
- 500 other: mg/kg bw
- Remarks:
- i.p.
- Dose / conc.:
- 1 000 other: mg/kg bw
- Remarks:
- i.p.
- Dose / conc.:
- 200 mg/kg bw/day
- Remarks:
- gavage
- No. of animals per sex per dose / concentration:
- no data
- Control animals:
- yes, concurrent vehicle
- Positive control reference chemical:
- Pre-treatment with 3-methylcholanthrene (3-MC), 20 mg/kg bw/day on 2 consecutive days; or phenobarbital (PB), single i.p. injection of 80 mg/kg bw in saline, followed by 0.1 % PB in the drinking water for 1 week.
- Details on dosing and sampling:
- not applicable, in vitro
- Statistics:
- no data
- Metabolites identified:
- yes
- Details on metabolites:
- One major phenolic metabolite of PANA was identified in experiments with rat hepatocytes, very likely 4-hydroxy-PANA, but the identity could not be confirmed completely. The metabolite was formed by cytochrome P-450-dependent monooxygenases via the epoxide pathway, as demonstrated in the experiments with rat liver microsomes pre-treatment with 3-MC and PB. Furthermore, pre-treatment of rats with PANA was also able to induce microsomal CYP450-dependent monooxygenases. No formation of 1-naphtylamine was detected.
- Endpoint:
- dermal absorption in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 23 Sep 2020 to 19 Mar 2021
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 428 (Skin Absorption: In Vitro Method)
- Version / remarks:
- Adopted: 13 April 2004
- Deviations:
- no
- GLP compliance:
- yes
- Radiolabelling:
- yes
- Species:
- other: Human Skin Donors
- Type of coverage:
- open
- Vehicle:
- other: neat compound, rubber matrix and base oil for lubricants
- Duration of exposure:
- The exposure period was terminated at 8 h after dosing. At 24 hours post dose, i.e. after 16 hours monitoring period, each diffusion cell was dismantled and the skin removed. See any other information on material and methods for further details.
- Doses:
- - Nominal doses: 1 % and 5 % in base oil for lubricants, 100 % as neat powder and 0.5 % and 3.5 % in rubber matrix
- Actual doses: 1.04 % (w/v), 5.34 % (w/v), 100 % (w/w), 0.409 % (w/w), 3.17 % (w/w)
- Actual doses calculated as follows: Seven representative weighed discs per dose were collected throughout dosing, seven representative aliquots of test preparation 1 and 2 (1 and 5% in base oil for lubricants) were dispensed into vials at the time of dosing and seven representative aliquots of the test preparation 3 (100% w/w) were collected immediately after dosing. All representative aliquots were analysed by liquid scintillation counting.
- Dose volume: 10 µL/cm² for 1% and 5% in base oil for lubricants, 5 mg/cm² for the 100% neat powder and 1 disc per skin sample for the 0.5% and 3.5% in rubber matrix (diameter of 20 mm and thickness 1120-1220 µm and 1150-1470 µm, respectively)
- Rationale for dose selection: in line with the ECHA final decision, several small dosages representative of the in-use conditions were chosen - No. of animals per group:
- A total of 12 samples of human split thickness skin membranes obtained from four different donors were used per test preparation.
- Details on study design:
- DOSE PREPARATION
- Method for preparation of dose suspensions:
After assessment of the radiochemical purity the radiochemical was diluted with non-radiolabelled PANA using ethanol (which was evaporated afterwards). The concentration and homogeneity of the mixture was assessed by liquid scintillation counting.
For test preparation 1 and 2, radiolabelled PANA was incorporated into a base oil for lubricants at a concentration of approx. 1 and 5 %, respectively.
For test preparation 4 and 5, radiolabelled PANA at a concentration of 0.5 and 3.5 % incorporated into a rubber disc by homogeneous mixing into a rubber mix. After mixing, the compounds are pressed into 1 mm thick mixture skins and discs with a diameter on 20 mm are punched out. Rubber disc containing 0.5 % and 3.5 % PANA respectively were applied to the skin samples.
APPLICATION OF DOSE:
Test preparation 1 and 2 were applied evenly over the surface of the exposed skin of 12 split thickness samples of human skin using a positive displacement pipette set to deliver ca 31.4 µL (10 µL/cm²). For [phenyl U 14C]-PANA in Test Preparation 3, water (31.4 µL) was applied to wet the skin surface. Test Preparation 3 was weighed into weighing boats (ca 15.7 mg) then tapped onto the skin surface and distributed evenly using a glass rod (application rate of 5 mg/cm²)
For test preparation 4 and 5 the skin surface was wetted prior to dosing with water (10 µL/cm²) and a single disc was applied using tweezers to a minimum of 12 skin samples. A glass rod was used to press down the disc to the skin.
VEHICLE
- Justification for use and choice of vehicle: rubber matrix and base oil for lubricants, representative of in-use conditions
TEST SITE
- Preparation of test site: The glass static diffusion cells were placed in a manifold on a magnetic stirrer plate heated via a circulating water bath to maintain the skin surface temperature at 32°C ± 1°C. The actual cell temperatures (ranging from 31.1°C to 32.6°C) were calibrated prior to mounting the skin membranes.
Magnetic stirrer bars were placed in the receptor fluid chambers which were filled with receptor fluid. Once thawed, sections of split thickness skin (ca 3 x 3 cm) were cut and mounted in the diffusion cells between the donor and receptor chamber. The donor chamber was tightened into place with a clamp. Cells were visually checked to ensure no cells were leaking and no air bubbles were present in the receptor fluid chamber.
Skin samples were allowed to equilibrate at 32°C ± 1°C for a minimum of 5 min. PBS (3 mL) was then added to the donor chamber and the skin samples were allowed to equilibrate for a further minimum of 30 min. The electrical resistance was then measured using a Tinsley Databridge (Model 6401) set at low voltage alternating current, 1000 Hz with a maximum voltage of 300 mV root mean squared (rms) in the parallel equivalent circuit mode. Any skin sample exhibiting a resistance less than 4.0 kΩ was excluded from subsequent absorption measurements. The PBS was removed from the skin surface; the skin was rinsed with water and dried with a tissue swab.
- Area of exposure: The surface area of exposed skin within the cells was 3.14 cm² with a receptor chamber volume of ca 10 mL (nominal).
REMOVAL OF TEST SUBSTANCE
- Washing procedures and type of cleansing agent: Commercial hand wash soap (ca 50 µL) was applied to the skin and the soap gently rubbed onto the skin with a tissue swab. The skin was then rinsed with ca 5 mL of a ca 2% (v/v) commercial soap solution. The soap solution was applied in aliquots (1 mL) and each aliquot was aspirated three times with a pipette. The skin was dried with a tissue swab. The process was repeated and the skin was dried with an additional tissue swab.
- Time after start of exposure: The exposure period was terminated at 8 h after dosing.
SAMPLE COLLECTION
Prior to dosing, a 300 µL sample of receptor fluid was removed from the receptor chamber collection arm. The receptor fluid volume was then maintained by the addition of fresh receptor fluid up to the calibration line on the receptor chamber collection arm. Following sample collection, the receptor chamber collection arm was sealed with Parafilm® to prevent evaporation of receptor fluid.
Receptor fluid aliquots were collected at 1, 2, 4, 8 and 12 h post dose as described above. All receptor fluid samples were analysed by liquid scintillation counting.
- Terminal procedure:
At 24 h post dose, the cell were dismantled and the donor chamber were retained for analysis (donor chamber wash). Skin was removed from the cell and placed on a piece of tissue paper to remove any remaining receptor fluid from the underside of the skin. The tissue was placed in the receptor wash pot for that particular cell.
The stratum corneum was removed with 20 successive tape strips. The skin sample was rotated 90° after each tape strip. Rotation was stopped if the epidermis/dermis junction became fragile or if epidermis was removed. Each tape was analysed individually by liquid scintillation counting.
The skin under the cell flange (unexposed skin) was cut away from the exposed skin. Each exposed skin sample was wrapped in a piece of clingfilm. A ca 200 g weight was heated to ca 65°C in a water bath and placed onto the epidermal surface for ca 90 s. The epidermis was then separated from the dermis using a scalpel. The clingfilm was retained for analysis.
Bulk receptor fluid (ca 10 mL) was removed from each receptor chamber and retained for analysis.
The receptor chambers were rinsed with ethanol (40 mL). The solvent was pooled as a single sample into the pre weighed receptor wash pot and sample weights were taken.
Total radioactivity was analysed in all samples of skin, receptor fluid, and washes by liquid scintillation counting.
SAMPLE PREPARATION
- Storage procedure: All samples were stored at ambient temperature for analysis. Following analysis, bulk samples were stored in a freezer set to maintain a temperature of -20°C.
- Preparation details: Skin samples were solubilised using Solvable® prior to analysis by liquid scintillation counting.
ANALYSIS
- Method type(s) for identification: All samples prepared in scintillation fluid were subjected to liquid scintillation counting, together with representative blank samples, using a Liquid Scintillation Analyser with automatic quench correction by an external standard method.
- Limits of detection and quantification: A limit of reliable measurement of 30 d.p.m. above background has been instituted
- Details on in vitro test system (if applicable):
- SKIN PREPARATION
- Source of skin: Eight donors were obtained from Tissue Solutions Ltd and two donors were obtained from BioIVT. The samples arrived at Charles River frozen and were stored in a freezer set to maintain a temperature of 20°C until used in the study.
- Donor information: 10 donors (male and female) aged 32 to 58 years old
- Ethical approval if human skin: Ethical approval for receipt and use of human skin has been obtained (Lothian Local Research Ethics Committee, REC Reference No. 06/S1101/19 and Glasgow Royal Infirmary REC, REC Reference No. 08/S0704/30). Tissue is regularly sourced from hospitals and tissue banks.
- Type of skin: full-thickness human skin (abdomen)
- Preparative technique: Human skin samples were removed from -20°C storage and allowed to thaw at ambient temperature. The thickness of the full thickness skin membranes was measured using a micrometer. Split-thickness membranes were prepared by pinning the full thickness skin, stratum corneum uppermost, onto a raised cork board and cutting with an electric dermatome (Zimmer®) at a setting equivalent to 200 400 µm depth. The thickness of the membranes was measured using a micrometer. Membranes were then wrapped in foil, placed into a self sealing bag and stored in a freezer, set to maintain a temperature of -20°C, for a maximum period of two months.
A static diffusion cell system (PermeGear Inc) was used.
- Thickness of skin (in mm): split-thickness range from 0.38 to 0.4 mm
- Membrane integrity check: Skin samples were allowed to equilibrate at 32°C ± 1°C for a minimum of 5 min. PBS (3 mL) was then added to the donor chamber and the skin samples were allowed to equilibrate for a further minimum of 30 min. The electrical resistance was then measured using a Tinsley Databridge (Model 6401) set at low voltage alternating current, 1000 Hz with a maximum voltage of 300 mV root mean squared (rms) in the parallel equivalent circuit mode. Any skin sample exhibiting a resistance less than 4.0 kΩ was excluded from subsequent absorption measurements. The PBS was removed from the skin surface; the skin was rinsed with water and dried with a tissue swab.
- Storage conditions: -20°C
- Justification of species, anatomical site and preparative technique: The human has been chosen for the safety evaluation as workers and consumers will be exposed during handling of the test item or the use of products containing the test item.
PRINCIPLES OF ASSAY
- Diffusion cell: A static cell diffusion system was used.
- Receptor fluid: Phosphate buffered saline (PBS) containing polyoxyethylene 20 oleyl ether (PEG, ca 6%, w/v), sodium azide (ca 0.01%, w/v), streptomycin (0.1 mg/mL) and penicillin (100 units/mL) with the pH confirmed and adjusted to 7.4 ± 0.1 if required.
- Solubility of test substance in receptor fluid: The target concentration (2.198 mg/mL) represented the maximum concentration of test item in the receptor fluid based on the entire applied dose being absorbed in 24 h from the 3.5% (w/w) rubber discs. As 83.78% of the target concentration was recovered, the receptor fluid was accepted for use on the study. The maximum absorption (equivalent to 5.11 µg/mL, Cell 5) was greatly below this level in the study, showing the receptor fluid was not rate limiting.
- Static system: The static diffusion cells was positioned in a steel manifold and heated via a circulating water bath to maintain a skin surface temperature
- Test temperature: 32 +/- 1 °C
- Occlusion: The donor chambers were not occluded and left open to the atmosphere - Signs and symptoms of toxicity:
- no effects
- Dermal irritation:
- no effects
- Absorption in different matrices:
- - Skin wash:
Test preparation 1: 20.03 ± 9.14 % applied dose;
Test preparation 2: 30.28 ± 15.35 % applied dose;
Test preparation 3: 32.58 ± 7.60 % applied dose;
Test preparation 4: 0.07 ± 0.03 % applied dose;
Test preparation 5: 0.13 ± 0.10 % applied dose
- Skin test site:
Test preparation 1: 94.60 ± 3.24 % applied dose;
Test preparation 2: 93.84 ± 23.96 % applied dose;
Test preparation 3: 94.76 ± 1.49 % applied dose;
Test preparation 4: 98.05 ± 1.26 % applied dose;
Test preparation 5: 100.57 ± 1.50 % applied dose
- Skin, untreated site:
Test preparation 1: °0.40 ± °0.69 % applied dose;
Test preparation 2: °0.30 ± °0.88 % applied dose;
Test preparation 3: °0.01 ± °0.01 % applied dose;
Test preparation 4: °0.00 ± °0.00 % applied dose;
Test preparation 5: °0.00 ± °0.00 % applied dose
- Receptor fluid, receptor chamber, donor chamber (in vitro test system):
Receptor fluid:
Test preparation 1: 1.78 ± 0.85 % applied dose;
Test preparation 2: 1.66 ± 0.54 % applied dose;
Test preparation 3: 0.08 ± 0.04 % applied dose;
Test preparation 4: 0.22 ± 0.06 % applied dose;
Test preparation 5: 0.24 ± 0.07 % applied dose
Receptor chamber:
Test preparation 1: °0.28 ± °0.16 % applied dose;
Test preparation 2: 0.22 ± 0.17 % applied dose;
Test preparation 3: °0.02 ± °0.01 % applied dose;
Test preparation 4: °0.03 ± °0.01 % applied dose;
Test preparation 5: °0.03 ± °0.01 % applied dose
- Stratum corneum (in vitro test system):
Stratum Corneum 1-2:
Test preparation 1: 0.24 ± 0.20 % applied dose;
Test preparation 2: 0.37 ± 0.33 % applied dose;
Test preparation 3: 0.24 ± 0.18 % applied dose;
Test preparation 4: 0.01 ± 0.01 % applied dose;
Test preparation 5: 0.01 ± 0.01 % applied dose
Stratum Corneum 3-20:
Test preparation 1: 0.65 ± 0.44 % applied dose;
Test preparation 2: 1.14 ± 1.16 % applied dose;
Test preparation 3: 0.18 ± 0.11 % applied dose;
Test preparation 4: 0.02 ± 0.03 % applied dose;
Test preparation 5: 0.03 ± 0.02 % applied dose
°=Mean includes results calculated from data less than 30 d.p.m above background - Total recovery:
- - Total recovery:
Test preparation 1: 100.49 ± 1.39 % applied dose;
Test preparation 2: 100.16 ± 23.47 % applied dose;
Test preparation 3: 95.96 ± 1.30 % applied dose;
Test preparation 4: 98.38 ± 1.24 % applied dose;
Test preparation 5: 100.93 ± 1.51 % applied dose
- Recovery of applied dose acceptable: Mass balance should be within 85-115%. However, if the mass balance was below 85% and the loss can be explained, the samples may also be accepted.
- Results adjusted for incomplete recovery of the applied dose:
The mass balance for most individual samples was within 100 ± 15% except for 4 samples for test preparation 2: Cell 37 (137.01%), Cell 38 (55.79%), Cell 39 (138.06%) and Cell 40 (73.04%). IncIt is thought that an error occurred during the wash for this study, as if the tissue swab values were swapped with the cells’ donor pair mass balance for each cell would be acceptable. Incorrect dosing has also been excluded as the same pipette and pipette setting were used throughout dosing. For these reasons, cells have been included in calculations..
- Limit of detection (LOD): A limit of reliable measurement of 30 d.p.m. above background has been instituted in these laboratories.
- Quantification of values below LOD or LOQ: Counts that are below 30 d.p.m. above background represent a true value. This means that data are recorded with values that are less than the limit of reliable measurement and marked. - Time point:
- 24 h
- Dose:
- 1%
- Parameter:
- percentage
- Absorption:
- 5.6 %
- Time point:
- 24 h
- Dose:
- 5%
- Parameter:
- percentage
- Absorption:
- 6.4 %
- Time point:
- 24 h
- Dose:
- 100%
- Parameter:
- percentage
- Absorption:
- 0.66 %
- Time point:
- 24 h
- Dose:
- 0.5%
- Parameter:
- percentage
- Absorption:
- 0.35 %
- Time point:
- 24 h
- Dose:
- 3.5%
- Parameter:
- percentage
- Absorption:
- 0.38 %
- Conversion factor human vs. animal skin:
- not applicable
- Conclusions:
- Following topical application of [phenyl U 14C]PANA to human skin in vitro dermal absorption after accounting for variability between replicates is 0.38% (17.6 μg equiv./cm²) of the applied dose in rubber discs (ca 3.5%, w/w), 0.35% (1.91 μg equiv./cm²) of the applied dose in rubber discs (ca 0.5%, w/w), 5.6% (5.84 μg equiv./cm²) of the applied dose in Test Preparation 1 (ca 1%, w/v), 6.4% (34.4 μg equiv./cm²) of the applied dose in Test Preparation 2 (ca 5%, w/v), and 0.66% (33.4 μg equiv./cm²) of the applied dose in Test Preparation 3 (ca 100%, w/w).
- Executive summary:
The test item, N‑1‑naphthylaniline (PANA) is used as an antioxidant in various oils such as lubricants and in the production of rubber. As part of the safety evaluation of PANA, a study was conducted to assess the absorption following dermal application in accordance with the OECD 428 and under GLP compliance. Exposure to the test item could occur during handling of the pure compound and during processing, for example, after dilution in a base oil for lubricants or after incorporation into a rubber matrix. Concentrations of PANA tested within the scope of this study represented the neat product (ca 100% (w/w) moistened with water); and relevant in-use concentrations diluted in base oil for lubricants (ca 5% (w/v) and ca 1% (w/v)). Due to the use pattern of the test item, a rubber matrix was selected to generate a relevant and technically feasible test sample representing a worst-case sample of the test item using a simplified manufacturing method based on the actual industrial processing (ca 3.5% (w/w) and ca 0.5% (w/w) in a rubber disc).
Split‑thickness human skin membranes were mounted into static diffusion cells in vitro. Receptor fluid was added to the receptor chamber (nominal volume 10 mL, nominal exposure area 3.14 cm2). The skin surface temperature was maintained at 32°C ± 1°C throughout the experiment. An electrical resistance barrier integrity assessment was performed and any skin sample exhibiting resistance lower than 4.0 kΩ was excluded from subsequent absorption measurements.
The rubber discs and Test Preparation 1-3 were applied to human split‑thickness skin membranes from four to six different donors and the cells were left open to the atmosphere. Test item stability following dosing was confirmed by high performance liquid chromatography (HPLC).
Percutaneous absorption was assessed by collecting receptor fluid at 1, 2, 4, 8 and 12 h post dose. At 8 h post dose, the exposure period was terminated by removing the rubber disc (if applicable) then washing the skin surface with a concentrated commercial hand wash soap followed by rinsing with a dilute soap solution (2%, v/v) and drying the surface with tissue paper. At 24 h post dose, the skin was then removed from the static cells, the stratum corneum tape stripped and the skin divided into exposed and unexposed skin. The exposed skin was heat separated into dermis and epidermis samples. The bulk receptor fluid was collected from the receptor chamber and retained for analysis. The donor chambers and receptor chambers were rinsed with ethanol and the samples retained for analysis. The skin samples were dissolved with Solvable™ tissue solubilizer. All samples were analysed by liquid scintillation counting.
Following topical application of [phenyl U 14C]PANA to human skin in vitro, dermal absorption after accounting for variability between replicates is 0.38% (17.6 μg equiv./cm²) of the applied dose in rubber discs (ca 3.5%, w/w), 0.35% (1.91 μg equiv./cm²) of the applied dose in rubber discs (ca 0.5%, w/w), 5.6% (5.84 μg equiv./cm²) of the applied dose in Test Preparation 1 (ca 1%, w/v), 6.4% (34.4 μg equiv./cm²) of the applied dose in Test Preparation 2 (ca 5%, w/v), and 0.66% (33.4 μg equiv./cm²) of the applied dose in Test Preparation 3 (ca 100%, w/w).
Referenceopen allclose all
Tissue distribution
Distribution of radioactivity in rat tissues 24 hours after oral administration of14C-PNA:
Tissue |
14C-PNA Equivalent µg/g wet tissue |
Percent of administered dose |
Heart |
6.49 |
0.0130 |
Lung |
10.2 |
0.0280 |
Pancreas |
3.62 |
0.00432 |
Spleen |
3.18 |
0.00377 |
Kidney |
28.7 |
0.123 |
Testes |
3.30 |
0.0200 |
Liver |
33.8 |
0.415 |
Fat |
66.0 |
2.35 |
Stomach |
488 |
5.62 |
Small intestine (+ contents) |
235 |
5.34 |
Caeca |
362 |
5.67 |
Large intestine (+ contents) |
435 |
3.10 |
Metabolism
Distribution of radioactivity in 0-48 hr pooled urine samples:
Fraction |
Percent of total radioactivity in the urine |
Ether extract (pH 12) |
16 |
Ether extract (pH 2) |
19 |
Aqueous residue (unextractable) |
65 |
Retention volumes and relative abundance of14C-PNA metabolites in the ether extract (pH 2):
14C-Compound |
HPLC Retention Volume (ml) |
% of14C in the Extract |
Area A 1 |
2.3 |
14 |
2 |
3.4 |
20 |
3 |
4.2 |
11 |
4 |
5.8 |
|
5 |
7.5 |
|
6 |
9.0 |
Σ 18 |
Area B |
12.0 |
23 |
Area C |
14.5 |
14 |
PNA |
28.0 |
0 |
Relative rates of microsomal metabolism of PANA by various treatments:
Pre-treatment |
Dose (mg/kg) |
No. of treatment |
Sex |
Rate, nmoles/min/mg protein |
Control |
-- |
-- |
Male |
0.18 ± 0.03 |
PB |
40 |
1 |
Male |
0.29 ± 0.02* |
MC |
20 |
2 |
Male |
0.30 ± 0.04* |
Control |
-- |
-- |
Male |
0.42 ± 0.01 |
PANA |
200 |
4 |
Male |
0.37 ± 0.04 |
Control |
olive oil |
-- |
Female |
0.24 ± 0.10 |
PANA |
200 |
8a |
Female |
0.60 ± 0.10* |
The data are mean of four single determination ± SD.
*P<0.05
a3 days/week for female rats by gastric intubation.
Effect of animal pre-treatment with inducers of monooxygenase activity:
|
|
|
|
|
Rates, nmoles/min/mg protein |
||
Pre-treatment |
Dose (mg/kg) |
No. of treatment |
Sex |
Cytochrome P-450 (nmoles/mg protein) |
Ethylmorphine demethylation |
Aldrin epoxydation |
Benzo[a]pyrene hydroxylation |
Control |
-- |
-- |
Male |
0.72 ± 0.08 |
7.40 ± 1.13 |
2.88 ± 0.36 |
0.24 ± 0.02 |
PB |
40 |
1 |
Male |
1.50 ± 0.11* |
14.20 ± 2.20 |
5.18 ± 1.00 |
0.42 ± 0.03* |
MC |
20 |
2 |
Male |
0.84 ± 0.07 |
7.20 ± 0.70 |
2.52 ± 0.40 |
0.76 ± 0.13* |
Control |
-- |
-- |
Male |
0.89 ± 0.05 |
5.65 ± 0.63 |
2.82 ± 0.21 |
0.24 ± 0.01 |
PANA |
200 |
1 |
Male |
0.95 ± 0.06 |
8.50 ± 1.60 |
3.10 ± 0.16 |
0.22 ± 0.03 |
|
500 |
1 |
Male |
1.12 ± 0.05* |
11.90 ± 0.13** |
4.54 ± 0.07** |
0.25 ± 0.04 |
|
1000 |
1 |
Male |
1.25 ± 0.03* |
12.20 ± 0.80** |
4.39 ± 0.20* |
0.23 ± 0.02 |
Control |
-- |
-- |
Male |
0.87 ± 0.04 |
8.61 ± 0.69 |
7.48 ± 0.47 |
0.22 ± 0.04 |
P1NA |
200 |
4 |
Male |
1.03 ± 0.03* |
13.41 ± 1.56 |
5.38 ± 0.45 |
0.30 ± 0.03 |
Control |
olive oil |
-- |
Female |
0.90 ± 0.12 |
0.71 ± 0.20 |
0.27 ± 0.04 |
0.02 ± 0.01 |
PANA |
200 |
8a |
Female |
0.92 ± 0.096 |
2.85 ± 0.41** |
0.47 ± 0.08 |
0.10 ± 0.02** |
Microsomes from male or female rats weighing 150 g were assayed. The data are mean of four single determinations ± SD.
*P<0.05; **P<0.01.
a3 days/week by gastric intubation.
Description of key information
Available experimental data on absorption, distribution, metabolism and excretion (ADME) are used to assess the absorption behaviour of N-phenyl-1-naphthylamine and, in the absence of sufficient data, default assumptions are made following the worst case.
Animal data on rats demonstrated that N-phenyl-1-naphthylamine is well absorbed after ingestion and is readily excreted; accumulation in the body is not expected. In vitro studies showed that the metabolism occurs primarily via hydroxylation.
Since the study results suggest that the substance is well absorbed via oral route, it cannot be concluded that the oral absorption is significantly less than 100%. Thus, in accordance with ECHA’s Endpoint specific guidance R.7c (v3.0, June 2017) a default value of complete (i.e., 100%) oral absorption is assumed.
According to ECHA’s Endpoint specific guidance Chapter R.7c (v3.0, June 2017) a default value of 100% skin absorption is generally used when the molecular mass of the substance is below 500 g/mol and the log P value is in the range of -1 to 4. Also, it is generally assumed that dermal absorption will not be higher than oral absorption.
A skin absorption study following OECD
428 was performed due to the ECHA final decision and the assumption,
that dermal absorption of N-phenyl-1-naphthylamine is significantly
lower than the default value.
Based on the available dermal absorption study the obtained dermal
absorption values are 0.66 % for the neat compound, 0.38 % for 3.5 % in
rubber matrix, 0.35 % for 0.5 % in rubber matrix, 5.6 % for 1% in base oil
for lubricants and 6.4 % for 5 % in base oil for lubricants. Thus, as
key values for the chemical safety assessment dermal absorption is set
to 0.66 % for the neat compound (100%), to 5.6 % for lubricant
formulations at and below 1%, to 6.4 % for lubricant formulations at and
above 5 % and as a worst case to 0.38 % for rubber formulations at 1-5 %.
With regard to inhalation, in the absence of bioavailability data it is most precautionary to assume that 100% of the inhaled vapour is bioavailable. Considering the lack of route-specific information when deriving a “no effect level” for inhalation a default safety factor of 2 is included for route-to-route extrapolation (oral-to-inhalation extrapolation), in line with ECHA's Guidance R.8.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 0.66
- Absorption rate - inhalation (%):
- 100
Additional information
Absorption following oral exposure
Male Sprague-Dawley rats were orally administered a single dose of 160 mg/kg bw [14C] N-phenyl-1-naphtylamine. The test material was well absorbed, metabolised almost completely excreted via faeces and urine (Sikka et al., 1981). Radioactivity was detected in plasma within 60 min, with the maximum concentration measured after 4 hours. After 24 hours, 20% of the radioactivity was found in the gastrointestinal tract, 2.4% in fatty tissue, 0.4% in the liver, and 0.1% in the kidneys. More than 90% of the administered dose had been excreted within 48 hours after administration. The primary route of excretion of radioactivity was via the feces (60%), although appreciable amounts of 14C were also excreted via the urine (32%). In the ether extract of the urine, using HPLC analysis at least five 14C-metabolites were detected, but no N-phenyl-1-naphthylamine could be determined in the ether extracts. The elimination half-lives were reported as 1.68 hours for the fast elimination and 33 hours for the slow elimination. Mono- and di-hydroxylated derivatives of have been detected in in vitro metabolic studies conducted with rat liver microsomes. Sikka et al. (1981) suggested that the metabolism ofis primarily via hydroxylation and subsequently undergoes with O-glucuronidation or O-sulfation. In the mono-hydroxy derivative, the hydroxy group is in the naphthalene moiety at the position para to the amino group and in the di-hydroxy derivative, at least one hydroxy group is at the available para position in the naphthyl ring. In the in vitro (rat heptic microsomes) metabolism study of Xuanxian and Wolff (1992), only a mono-hydroxylated metabolite was identified. Pretreatment of male rats with phenobarbital or 3-methylcholanthrene increased the rate of microsomal metabolism of, indicating that more than one P-450 monooxygenase mediates the reaction. The formation of 1-naphthylamine via eliminiation of the phenol group of the hydroxylated metabolites is not expected. Based on the chemical structure, it is unlikely that it is metabolised to the carcinogenic 2-naphthylamine.
Absorption following dermal exposure
As part of the safety evaluation of PANA, a study was conducted to assess the absorption following dermal application in accordance with the OECD 428 and under GLP compliance. Exposure to the test item could occur during handling of the pure compound and during processing, for example, after dilution in a base oil for lubricants or after incorporation into a rubber matrix. Concentrations of PANA tested within the scope of this study represented the neat product (ca 100% (w/w) moistened with water); and relevant in-use concentrations diluted in base oil for lubricants (ca 5% (w/v) and ca 1% (w/v)). Due to the use pattern of the test item, a rubber matrix was selected to generate a relevant and technically feasible test sample representing a worst-case sample of the test item using a simplified manufacturing method based on the actual industrial processing (ca 3.5% (w/w) and ca 0.5% (w/w) in a rubber disc).
Split‑thickness human skin membranes were mounted into static diffusion cells in vitro. Receptor fluid was added to the receptor chamber (nominal volume 10 mL, nominal exposure area 3.14 cm2). The skin surface temperature was maintained at 32°C ± 1°C throughout the experiment. An electrical resistance barrier integrity assessment was performed and any skin sample exhibiting resistance lower than 4.0 kΩ was excluded from subsequent absorption measurements.
Following topical application of [phenyl U 14C]PANA to human skin in vitro, dermal absorption after accounting for variability between replicates is 0.38% (17.6 μg equiv./cm²) of the applied dose in rubber discs (ca 3.5%, w/w), 0.35% (1.91 μg equiv./cm²) of the applied dose in rubber discs (ca 0.5%, w/w), 5.6% (5.84 μg equiv./cm²) of the applied dose in Test Preparation 1 (ca 1%, w/v), 6.4% (34.4 μg equiv./cm²) of the applied dose in Test Preparation 2 (ca 5%, w/v), and 0.66% (33.4 μg equiv./cm²) of the applied dose in Test Preparation 3 (ca 100%, w/w).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.